Merck’s Keytruda gets FDA priority review for a high-risk form of bladder cancer
Will it take a miracle for Biogen’s aducanumab to get approved?
Neurocrine pays $50M for rights to an epilepsy drug
FDA guidance finally opens doors for insulin biosimilars
*please scroll down for all the latest news*
Want to stay updated on CP happenings? New features, new boards, CP wire articles, and more? Click here to subscribe
